D. McCabe

发表

Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis

N. Camp, A. Cox, G. Duff, 2005, Genes and Immunity.

Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data.

J. Frazier, A. Bendele, T. Mcabee, 1999, Arthritis and rheumatism.

Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose–response analysis

R. Rojo, S. Shoji, S. Kolluri, 2016, Journal of Pharmacokinetics and Pharmacodynamics.

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.

Stanley B. Cohen, J. Kremer, M. Weinblatt, 2002, Arthritis and rheumatism.

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

Z Domljan, B. Bresnihan, P. Emery, 1998, Arthritis and rheumatism.

The Effectiveness of a Weak Opioid Medication versus a Cyclo-Oxygenase-2 (COX-2) Selective Non-Steroidal Anti-Inflammatory Drug in Treating Flare-Up of Chronic Low-Back Pain: Results from Two Randomized, Double-Blind, 6-Week Studies

D. McCabe, W. Spalding, JB O'Donnell, 2009, The Journal of international medical research.

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.

H. Genant, B. Bresnihan, Yebin Jiang, 2000, Arthritis and rheumatism.

Efficacy of low-dose celecoxib in patients with acute pain.

B. Schachtel, D. McCabe, M. Berger, 2011, The journal of pain : official journal of the American Pain Society.

Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis.

M. Weisman, L. Moreland, J. Dayer, 2000, The Journal of rheumatology.

FRI0036 Population pharmacokinetics (pk) of anakinra in subjects with rheumatoid arthritis (ra)

J. Frazier, D. McCabe, B. Yang, 2001 .

Effects of Interleukin-1 Receptor Antagonist in a Slow-Release Hylan Vehicle on Rat Type II Collagen Arthritis

J. Frazier, A. Bendele, T. Mcabee, 1998, Pharmaceutical Research.

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.

B. Bresnihan, G. Nuki, D. McCabe, 2002, Arthritis and rheumatism.

Deposition of low dose benzo(a)pyrene into fetal tissue: influence of protein binding.

D. McCabe, E. Flynn, 1990, Teratology.

Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study

V. Strand, E. Lee, F. Buttgereit, 2019, RMD Open.

SAT0221 Efficacy and Safety of PF-04171327, a Novel Dissociated Agonist of the Glucocorticoid Receptor (DAGR): Results of a Phase 2, Randomized, Double-Blind Study

V. Strand, F. Buttgereit, R. Rojo, 2015 .